Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_assertion type Assertion NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_head.
- NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_assertion description "[Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_provenance.
- NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_assertion evidence source_evidence_literature NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_provenance.
- NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_assertion SIO_000772 17667919 NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_provenance.
- NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_assertion wasDerivedFrom befree-20140225 NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_provenance.
- NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_assertion wasGeneratedBy ECO_0000203 NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_provenance.